BPH 수술 치료 시장(-2030년) : 유형, 약제 유형, 치료, 최종 사용자 세계 예측(-2030년)

The global BPH surgical treatment market is valued at an estimated 12.62 billion in 2024 and is projected to reach USD 17.19 billion by 2030, at a CAGR of 5.3% during the forecast period. The growing elderly male population is leading to the cause of BPH patients globally. Therefore, BPH is related to age, and aging is known as a risk factor for BPH. Approximately 50% of men over the age of 50 and around 80% of men over the age of 70 are under the influence of BPH.

In 2023, the alpha-blockers segment accounted for the largest share of the BPH surgical treatment market, by drug type.

Alpha-blockers, 5-alpha reductase inhibitors, and other drug types make up the drug-type-based segments of the BPH surgical treatment market. Market share for BPH surgical treatment was highest in the Alpha-blockers in 2023. This is mainly due to the Alpha-blockers being recommended as first-line treatment for BPH. a-blockers relax the smooth muscle of the prostate and bladder neck to improve urine flow and reduce bladder outlet obstruction.

"The home care settings segment is projected to witness the highest growth rate in BPH surgical treatment market, by the end-user, during the forecast period."

Based on end users, the BPH surgical treatment market is segmented into hospitals, ambulatory surgery centers & clinics, and home care settings. The driving factors that force home care settings to BPH surgical treatment is that the patients prefer taking medicine over surgery in most cases, which has supported the growth of this segment. Also, patients avoid surgical or minimally invasive procedures (e.g., TURP, laser therapy) due to potential complications, discomfort, or recovery time.

"The Asia Pacific region is projected to witness highest growth rate in the BPH surgical treatment market during the forecast period"

The global BPH surgical treatment market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. Throughout the forecast period, the BPH surgical treatment market is expected to grow at the fastest rate in the Asia Pacific region. The demand for BPH surgical treatment in the APAC is mainly driven by the growing geriatric population, the increasing GDP of Asian countries, the rising healthcare expenditure in the APAC countries, and growing public awareness.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 50%, Tier 2 - 30%, and Tier 3 - 20%
• By Designation: C-level - 25%, D-level - 20%, and Others - 55%
• By Region: North America - 35%, Europe - 32%, Asia Pacific - 21%, Latin America - 8%, Middle East & Africa - 1%, and the GCC Countries - 3%

Lists of Companies Profiled in the Report:

GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), Astellas Pharma Inc.(Japan), Viatris Inc. (US), Asahi Kasei Corporation (Japan), Organon & Co. (US), Alembic Pharmaceuticals Limited (India), Teleflex Incorporated (US) and Boston Scientific Corporation (US), Olympus Corporation (Japan), Procept BioRobotics Corporation (US), Coloplast Group (Denmark), IPG Photonics Corporation (Russia), ProstaLund AB (Sweden), Karl Storz Se & Co. KG (Germany), Richard Wolf Gmbh (Germany), and Quanta System (Italy), Asclepion Laser Technologies GmbH (Germany), Cook Medical (US), SRS Medical (US), Pnn Medical A/S (Denmark), Allium Ltd. (Israel), Urologix, LLC (US), and Medifocus, Inc. (Canada).

Research Coverage:

In this report, the BPH surgical treatment market has been categorized based on drug type (alpha-blockers, 5-alpha reductase inhibitors, and other drug types), type (Transurethral Resection of the Prostate (TURP), Laser Surgery, UroLift Procedure, Rezum Procedure, Robot-assisted waterjet ablation, Prostatic Stenting, Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Prostatic arterial embolization (PAE) and others) end user (hospitals, ASCs & clinics, and home care settings), therapy (monotherapy and combination drug therapy), and region (Europe, Middle East & Africa, North America, Latin America, Asia Pacific, and the GCC Countries).

Comprehensive information regarding the main drivers, barriers, opportunities, and challenges influencing the BPH surgical treatment market's expansion is included in detail in this study. An exhaustive study of the key players in the cochlear implants market has been done to provide insights into their business profiles, products offered, noteworthy strategies, product launches, and approvals, and other recent activities pertaining to the market.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall BPH surgical treatment market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, opportunities, and restraints.

The report provides insights on the following pointers:

• Analysis of key drivers: (Expanding aging population and increasing prevalence of BPH, Rising cases of obesity in males, and Growing preference for minimally invasive surgeries), restraints (High cost of cochlear implants and associated surgeries and surgical risks, procedural complications, and long post-surgery rehabilitation), opportunities (Side effects associated with BPH medications and High cost of BPH surgical treatment), and challenges (Shortage of skilled professionals, Low awareness regarding prostate health and Product recalls) influencing the growth of the in BPH surgical treatment market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the BPH surgical treatment market across varied regions.
• Product Development/Innovation: Comprehensive information about product development and new technologies - the report analyses the BPH surgical treatment market.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the BPH surgical treatment market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Viatris Inc. (US), Asahi Kasei Corporation (Japan), Organon & Co. (US), Alembic Pharmaceuticals Limited (India), Teleflex Incorporated (US) and Boston Scientific Corporation (US), Olympus Corporation (Japan), Procept BioRobotics Corporation (US), Coloplast Group (Denmark) and IPG Photonics Corporation (Russia) in the BPH surgical treatment market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 LIMITATIONS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach, by type
    • 2.2.1.2 Approach 1: Company revenue estimation approach, by drug type
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.4 MARKET SHARE ANALYSIS
  • 2.4.1 STUDY ASSUMPTIONS
  • 2.4.2 GROWTH RATE ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
  • 2.5.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.5.2 SCOPE-RELATED LIMITATIONS
• 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BPH SURGICAL TREATMENT MARKET OVERVIEW
• 4.2 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE AND COUNTRY (2024)
• 4.3 BPH SURGICAL TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 BPH SURGICAL TREATMENT MARKET: REGIONAL MIX (2024-2030)

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Expanding aging population and increasing prevalence of benign prostatic hyperplasia
    • 5.2.1.2 Rising cases of obesity in males
    • 5.2.1.3 Growing preference for minimally invasive surgeries
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Side effects associated with BPH medications
    • 5.2.2.2 High cost of BPH surgical treatment
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 High growth potential of emerging economies
    • 5.2.3.2 Favorable funding investments for BHP drug development
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Shortage of skilled professionals
    • 5.2.4.2 Low awareness regarding prostate health
    • 5.2.4.3 Product recalls
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 SUPPLY CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 PORTER'S FIVE FORCES ANALYSIS
  • 5.6.1 THREAT OF NEW ENTRANTS
  • 5.6.2 THREAT OF SUBSTITUTES
  • 5.6.3 BARGAINING POWER OF BUYERS
  • 5.6.4 BARGAINING POWER OF SUPPLIERS
  • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.7 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.7.2 BUYING CRITERIA
• 5.8 REGULATORY SCENARIO
  • 5.8.1 PHARMACEUTICAL INDUSTRY
    • 5.8.1.1 Regulatory requirements
      • 5.8.1.1.1 EU regulations
      • 5.8.1.1.2 US regulations
  • 5.8.2 MEDICAL DEVICES INDUSTRY
    • 5.8.2.1 US
    • 5.8.2.2 Canada
    • 5.8.2.3 Europe
    • 5.8.2.4 Asia Pacific
      • 5.8.2.4.1 Japan
      • 5.8.2.4.2 China
      • 5.8.2.4.3 India
    • 5.8.2.5 Latin America
      • 5.8.2.5.1 Brazil
      • 5.8.2.5.2 Mexico
    • 5.8.2.6 Middle East
    • 5.8.2.7 Africa
  • 5.8.3 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE TREND FOR UROLIFT, BY REGION, 2021-2023
  • 5.9.2 AVERAGE SELLING PRICING TREND FOR AVODART, BY REGION, 2021-2023
  • 5.9.3 AVERAGE SELLING PRICING TREND FOR BPH SURGICAL TREATMENT PROCEDURES, 2021-2023
• 5.10 TECHNOLOGY ANALYSIS
  • 5.10.1 KEY TECHNOLOGIES
    • 5.10.1.1 Minimally invasive surgical techniques
  • 5.10.2 COMPLEMENTARY TECHNOLOGIES
    • 5.10.2.1 Robotic & AI-assisted surgical systems
  • 5.10.3 ADJACENT TECHNOLOGIES
    • 5.10.3.1 MRI-ultrasound imaging
• 5.11 PESTLE ANALYSIS
• 5.12 PATENT ANALYSIS
• 5.13 TRADE ANALYSIS
  • 5.13.1 TRADE ANALYSIS FOR ENDOSCOPES
  • 5.13.2 TRADE ANALYSIS FOR TADALAFIL
• 5.14 KEY CONFERENCES & EVENTS, 2025-2026
• 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.16 IMPACT OF GENERATIVE AI/AI ON BPH SURGICAL TREATMENT MARKET
• 5.17 INVESTMENT & FUNDING SCENARIO

6 BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE

• 6.1 INTRODUCTION
  • 6.1.1 ALPHA-BLOCKERS
    • 6.1.1.1 Tamsulosin
      • 6.1.1.1.1 Oldest prescribed drug with minimal effects on blood pressure to fuel uptake
    • 6.1.1.2 Silodosin
      • 6.1.1.2.1 Launch of generics to boost demand
    • 6.1.1.3 Alfuzosin
      • 6.1.1.3.1 Associated side effects to restrain market adoption
    • 6.1.1.4 Doxazosin
      • 6.1.1.4.1 Ability to provide long-term results to fuel uptake
    • 6.1.1.5 Other alpha-blockers
  • 6.1.2 5-ALPHA REDUCTASE INHIBITORS
    • 6.1.2.1 Dutasteride
      • 6.1.2.1.1 Slow but gradual reduction in symptoms to boost demand
    • 6.1.2.2 Finasteride
      • 6.1.2.2.1 Ability to decrease PSA levels to support market growth
  • 6.1.3 OTHER DRUG TYPES

7 BPH SURGICAL TREATMENT MARKET, BY TYPE

• 7.1 INTRODUCTION
  • 7.1.1 TRANSURETHRAL RESECTION OF THE PROSTATE (TURP)
    • 7.1.1.1 Gold standard for BPH treatment to boost demand
  • 7.1.2 LASER SURGERIES
    • 7.1.2.1 Evolution in lasers and high efficacy to boost demand
  • 7.1.3 UROLIFT PROCEDURES
    • 7.1.3.1 High safety and convenience to boost demand
  • 7.1.4 REZUM PROCEDURES
    • 7.1.4.1 Convenience of being conducted in outpatient settings to support market growth
  • 7.1.5 ROBOT-ASSISTED WATERJET ABLATION
    • 7.1.5.1 Advanced real-time capabilities with image-guided features to propel market
  • 7.1.6 PROSTATIC STENTS
    • 7.1.6.1 Temporarily designed for short-term use to support market growth
  • 7.1.7 TRANSURETHRAL MICROWAVE THERMOTHERAPY (TUMT)
    • 7.1.7.1 Lower risk of bleeding without hospitalization to fuel market
  • 7.1.8 TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE (TUNA)
    • 7.1.8.1 Favorable reimbursement policies to boost demand
  • 7.1.9 PROSTATIC ARTERIAL EMBOLIZATION (PAE)
    • 7.1.9.1 Minimally invasive technique to fuel uptake
  • 7.1.10 OTHER PROCEDURES

8 BPH SURGICAL TREATMENT MARKET, BY THERAPY

• 8.1 INTRODUCTION
• 8.2 MONOTHERAPY
  • 8.2.1 UTILIZATION OF SINGLE MEDICATION TO PROPEL MARKET
• 8.3 COMBINATION DRUG THERAPY
  • 8.3.1 HIGH UTILIZATION FOR PATIENTS WITH RAPID PROGRESSION RATES TO DRIVE MARKET

9 BPH SURGICAL TREATMENT MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS
  • 9.2.1 HIGH PURCHASING POWER FOR ADVANCED BPH SURGICAL EQUIPMENT TO DRIVE MARKET
• 9.3 AMBULATORY SURGERY CENTERS & CLINICS
  • 9.3.1 LOWER COST AND SHORTER PATIENT STAYS TO PROPEL MARKET
• 9.4 HOME CARE SETTINGS
  • 9.4.1 CONVENIENCE AND COST-EFFICIENT BENEFITS TO FUEL MARKET

10 BPH SURGICAL TREATMENT MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Presence of key medical device manufacturers to boost demand
  • 10.2.3 CANADA
    • 10.2.3.1 Favorable federal funding for advanced BPH products to fuel market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Increasing healthcare expenditure to drive market
  • 10.3.3 UK
    • 10.3.3.1 Availability of innovative treatment options for UTIs to drive market
  • 10.3.4 FRANCE
    • 10.3.4.1 Favorable private & public healthcare investments to fuel market
  • 10.3.5 ITALY
    • 10.3.5.1 Rising geriatric population and subsequent rise in obesity to propel market
  • 10.3.6 SPAIN
    • 10.3.6.1 Increasing uptake of UroLift procedures to drive market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 JAPAN
    • 10.4.2.1 Mandatory health insurance programs to fuel uptake
  • 10.4.3 CHINA
    • 10.4.3.1 Rising demand for diagnostic procedures to drive market
  • 10.4.4 INDIA
    • 10.4.4.1 Expanding target patient population to drive market
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 High prevalence of obesity to support market growth
  • 10.4.6 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Rising incidence of cancer to support market growth
  • 10.5.3 MEXICO
    • 10.5.3.1 Popularity in medical tourism to drive market
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 DEMAND FOR ADVANCED HEALTHCARE DIAGNOSTICS TO FUEL UPTAKE
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 10.7 GCC COUNTRIES
  • 10.7.1 RISING HEALTHCARE BUDGETS AND GROWING AWARENESS OF BPH TO SUPPORT MARKET GROWTH
  • 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BPH SURGICAL TREATMENT MARKET
• 11.3 REVENUE ANALYSIS, 2021-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
• 11.5 COMPANY EVALUATION MATRIX, BY DRUG TYPE: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
• 11.6 COMPANY EVALUATION MATRIX, BY TYPE: KEY PLAYERS, 2023
  • 11.6.1 STARS
  • 11.6.2 EMERGING LEADERS
  • 11.6.3 PERVASIVE PLAYERS
  • 11.6.4 PARTICIPANTS
  • 11.6.5 COMPANY FOOTPRINT: KEY PLAYERS (DRUG TYPE AND TYPE), 2023
    • 11.6.5.1 Company footprint
    • 11.6.5.2 Region footprint
    • 11.6.5.3 Drug type footprint
    • 11.6.5.4 Type footprint
    • 11.6.5.5 End-user footprint
• 11.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.7.1 PROGRESSIVE COMPANIES
  • 11.7.2 RESPONSIVE COMPANIES
  • 11.7.3 DYNAMIC COMPANIES
  • 11.7.4 STARTING BLOCKS
  • 11.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 11.7.5.1 Detailed list of key startups/SMEs
    • 11.7.5.2 Competitive benchmarking of key startups
• 11.8 COMPANY VALUATION & FINANCIAL METRICS
• 11.9 BRAND/PRODUCT COMPARISON
• 11.10 COMPETITIVE SCENARIO
  • 11.10.1 PRODUCT LAUNCHES & APPROVALS
  • 11.10.2 DEALS
  • 11.10.3 EXPANSIONS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 GLAXOSMITHKLINE PLC
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 ELI LILLY AND COMPANY
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 TELEFLEX INCORPORATED
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches & approvals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 BOSTON SCIENTIFIC CORPORATION
    • 12.1.4.1 Business overview
    • 12.1.4.2 Recent developments
      • 12.1.4.2.1 Deals
      • 12.1.4.2.2 Expansions
    • 12.1.4.3 MnM view
      • 12.1.4.3.1 Key strengths
      • 12.1.4.3.2 Strategic choices
      • 12.1.4.3.3 Weaknesses & competitive threats
  • 12.1.5 PROCEPT BIOROBOTICS CORPORATION
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product approvals
      • 12.1.5.3.2 Expansions
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 ASTELLAS PHARMA INC.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
  • 12.1.7 ALEMBIC PHARMACEUTICALS LIMITED
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
  • 12.1.8 ASAHI KASEI CORPORATION
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
  • 12.1.9 ORGANON & CO.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Deals
  • 12.1.10 OLYMPUS CORPORATION
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Deals
  • 12.1.11 COLOPLAST GROUP
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
  • 12.1.12 IPG PHOTONICS CORPORATION
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
  • 12.1.13 VIATRIS INC.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
  • 12.1.14 ABBVIE INC.
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Deals
  • 12.1.15 PROSTALUND AB
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 KARL STORZ SE & CO. KG
  • 12.2.2 RICHARD WOLF GMBH
  • 12.2.3 UNILAB, INC.
  • 12.2.4 BIOLITEC HOLDING GMBH & CO KG
  • 12.2.5 UROLOGIX, LLC.
  • 12.2.6 ADVIN HEALTH CARE
  • 12.2.7 MEDIFOCUS, INC.
  • 12.2.8 JENASURGICAL (ASCLEPION LASER TECHNOLOGIES GMBH)
  • 12.2.9 PNN MEDICAL A/S
  • 12.2.10 SURGICAL LASERS INC.
  • 12.2.11 QUANTA SYSTEM
  • 12.2.12 ALLIUM LTD.
  • 12.2.13 SRS MEDICAL
  • 12.2.14 LABORIE MEDICAL TECHNOLOGIES
  • 12.2.15 COOK MEDICAL

13 APPENDIX

• 13.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.2 CUSTOMIZATION OPTIONS
• 13.3 RELATED REPORTS
• 13.4 AUTHOR DETAILS